207 related articles for article (PubMed ID: 11179339)
1. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice.
Gramzinski RA; Doolan DL; Sedegah M; Davis HL; Krieg AM; Hoffman SL
Infect Immun; 2001 Mar; 69(3):1643-9. PubMed ID: 11179339
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.
Kumar S; Jones TR; Oakley MS; Zheng H; Kuppusamy SP; Taye A; Krieg AM; Stowers AW; Kaslow DC; Hoffman SL
Infect Immun; 2004 Feb; 72(2):949-57. PubMed ID: 14742540
[TBL] [Abstract][Full Text] [Related]
3. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model.
Doolan DL; Hoffman SL
J Immunol; 1999 Jul; 163(2):884-92. PubMed ID: 10395683
[TBL] [Abstract][Full Text] [Related]
4. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
Liu Y; Luo X; Yang C; Yu S; Xu H
Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
[TBL] [Abstract][Full Text] [Related]
5. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection.
Harandi AM; Eriksson K; Holmgren J
J Virol; 2003 Jan; 77(2):953-62. PubMed ID: 12502811
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses.
Kitagaki K; Jain VV; Businga TR; Hussain I; Kline JN
Clin Diagn Lab Immunol; 2002 Nov; 9(6):1260-9. PubMed ID: 12414759
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
8. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice.
Su Z; Tam MF; Jankovic D; Stevenson MM
Infect Immun; 2003 Sep; 71(9):5178-87. PubMed ID: 12933862
[TBL] [Abstract][Full Text] [Related]
10. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
[TBL] [Abstract][Full Text] [Related]
12. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.
Charoenvit Y; Majam VF; Corradin G; Sacci JB; Wang R; Doolan DL; Jones TR; Abot E; Patarroyo ME; Guzman F; Hoffman SL
Infect Immun; 1999 Nov; 67(11):5604-14. PubMed ID: 10531206
[TBL] [Abstract][Full Text] [Related]
13. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
[TBL] [Abstract][Full Text] [Related]
14. Synthetic CpG-ODN rapidly enriches immune compartments in neonatal chicks to induce protective immunity against bacterial infections.
Gunawardana T; Ahmed KA; Goonewardene K; Popowich S; Kurukulasuriya S; Karunarathna R; Gupta A; Lockerbie B; Foldvari M; Tikoo SK; Willson P; Gomis S
Sci Rep; 2019 Jan; 9(1):341. PubMed ID: 30674918
[TBL] [Abstract][Full Text] [Related]
15. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
16. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms.
Walker PS; Scharton-Kersten T; Krieg AM; Love-Homan L; Rowton ED; Udey MC; Vogel JC
Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6970-5. PubMed ID: 10359823
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells.
Lenert P; Rasmussen W; Ashman RF; Ballas ZK
DNA Cell Biol; 2003 Oct; 22(10):621-31. PubMed ID: 14611683
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine.
Chawla B; Mahajan B; Oakley M; Majam VF; Belmonte A; Sedegah M; Shimp RL; Kaslow DC; Kumar S
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31308085
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
